{"name":"Fresenius Kabi SwissBioSim GmbH","slug":"fresenius-kabi-swissbiosim-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"MSB11456","genericName":"MSB11456","slug":"msb11456","indication":"HER2-positive breast cancer","status":"phase_3"},{"name":"MSB11022","genericName":"MSB11022","slug":"msb11022","indication":"HER2-positive breast cancer","status":"phase_3"},{"name":"US-licensed Prolia (Amgen)","genericName":"US-licensed Prolia (Amgen)","slug":"us-licensed-prolia-amgen","indication":"Treatment of osteoporosis in postmenopausal women at high risk of fracture, treatment to increase bone mass in men with osteoporosis, treatment to increase bone mass in women with osteoporosis due to sustained systemic glucocorticoid therapy, treatment of bone loss associated with hormone ablation in men with prostate cancer, treatment of bone loss in women with breast cancer, treatment of giant cell tumor of bone, treatment of hypercalcemia of malignancy, treatment of multiple myeloma, treatment of bone metastases in men with prostate cancer, treatment of bone metastases in women with breast cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"EU-approved RoActemra","genericName":"EU-approved RoActemra","slug":"eu-approved-roactemra","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"FKS518","genericName":"FKS518","slug":"fks518","indication":"Organ transplant rejection prevention","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EU-Humira","genericName":"EU-Humira","slug":"eu-humira","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"MSB11456","genericName":"MSB11456","slug":"msb11456","phase":"phase_3","mechanism":"MSB11456 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and blocking growth signaling.","indications":["HER2-positive breast cancer","HER2-positive gastric cancer"],"catalyst":""},{"name":"EU-Humira","genericName":"EU-Humira","slug":"eu-humira","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU-approved RoActemra","genericName":"EU-approved RoActemra","slug":"eu-approved-roactemra","phase":"phase_3","mechanism":"RoActemra (tocilizumab) is a humanized monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, reducing inflammatory signaling in immune-mediated diseases.","indications":["Rheumatoid arthritis","Giant cell arteritis","Polyarticular juvenile idiopathic arthritis","Systemic sclerosis-associated interstitial lung disease","COVID-19 (severe or critical)"],"catalyst":""},{"name":"FKS518","genericName":"FKS518","slug":"fks518","phase":"phase_3","mechanism":"FKS518 is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, thereby reducing immune-mediated rejection.","indications":["Organ transplant rejection prevention","Autoimmune diseases (investigational)"],"catalyst":""},{"name":"MSB11022","genericName":"MSB11022","slug":"msb11022","phase":"phase_3","mechanism":"MSB11022 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and inhibiting tumor growth.","indications":["HER2-positive breast cancer","HER2-positive gastric cancer"],"catalyst":""},{"name":"US-licensed Prolia (Amgen)","genericName":"US-licensed Prolia (Amgen)","slug":"us-licensed-prolia-amgen","phase":"phase_3","mechanism":"Prolia is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.","indications":["Treatment of osteoporosis in postmenopausal women at high risk of fracture, treatment to increase bone mass in men with osteoporosis, treatment to increase bone mass in women with osteoporosis due to sustained systemic glucocorticoid therapy, treatment of bone loss associated with hormone ablation in men with prostate cancer, treatment of bone loss in women with breast cancer, treatment of giant cell tumor of bone, treatment of hypercalcemia of malignancy, treatment of multiple myeloma, treatment of bone metastases in men with prostate cancer, treatment of bone metastases in women with breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxON0J2eXpqUkY2YjVIbmhxN21BNTlyMzBMRHBybW0yLVBqbTNnRDlFdDQzOXN5UGRBWHFQRDIxSXFjbVp6Sk51VldlRUx6SnZOMjN0YkU2Rl9HaUJIRnJtUzFKWUltTWoxQkhBeVVhX1ZlVDhoRTdYT0RtOEFSRmoxR1htampYV3RsaHNfdVl0MnN4OVVkMktXdVFzNV9BWkXSAVZBVV95cUxOZzV4RVhZN2ZycE9uTjdXYXY2Z3R3SFFEd2lDamhJTnhZTmdkVW9tRHV4U3Q5dy00SEF4a2tlTWwzOFpUUzkyRXVkSXVNWklyY0l1RXdYQQ?oc=5","date":"2026-03-23","type":"patent","source":"Law360","summary":"Fresenius Challenges Patents To Launch IBD Drug Biosimilar - Law360","headline":"Fresenius Challenges Patents To Launch IBD Drug Biosimilar - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNTnF4d1pfRFoxd2xzNU8tVXB3azZ1a19YUGxEc0dQOXoxdU5TMjhxN0dRelBLZ184a25lYXlaWFhRQzFyMHpGRHVRd2tfT1RhVUIyNkJJbEQzMXd2M19FOFZpdzJDcjdjbEFwOFRXNV80ZHlWeV9wbHJEZklhTUhhTHA2MHRwMmllb1dBdEkxMVcyTUEtUm1WWU530gFWQVVfeXFMUDAzNXFwcl9LVHFCSnR4Tm5QalhDU2xfRm12ODVXdl8wTEF0aDRNQndJM0gtMlZxS29EZDNfUUxGY3ZSb2c2NEd0cE9ybWFNRjB5MHNGZ2c?oc=5","date":"2025-11-21","type":"pipeline","source":"Law360","summary":"Squires Issues 57 More PTAB Denials, Broken Out By Type - Law360","headline":"Squires Issues 57 More PTAB Denials, Broken Out By Type - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPamI0dDdoRkVUeDRSY0Rrem9HOU9FY3IzbG9FdXJIZk5yMXdJZFg4a18ySk1tbHlMbHpLelM5ZUkzOXdzWXZ1WE40OE11a0F4a0JwbWdIcGMtem95Q2k2X1o2NGszMGItSGQtYXFXajY2WFB6emliQ09zTjl0a1VZTUdPWkk3dE9Hd25lMmdyOXFaa3VpNzRPc0lkVFJpV3VqSnc?oc=5","date":"2024-04-09","type":"patent","source":"BioWorld News","summary":"More biosimilars from China, US encroach on Amgen’s denosumab - BioWorld News","headline":"More biosimilars from China, US encroach on Amgen’s denosumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPUU43WXZMUzRlMUloc1kxM2J0cjhjMDRnRHc1OFpHWW9rSU5lS3lrN2p0V0VJRXF4OVpBdERUbURlY21HbWtra2FmakJzM2trNE05Q0dWU3pTNHgxbmNNNW1URDBlZHh0M0Ewd3I0c3QzZTlLdzFzWGZUQUxpYmtoOTdzNUl3YlVOOEtPeUZJc1BsMW01eFlXZ1ltQnRULUFJd3RLengxOXdPYUh5eDFIRw?oc=5","date":"2022-01-13","type":"patent","source":"IPWatchdog.com","summary":"Patent Filings Roundup: New Litigation-Funded Campaign; PTAB Denies Under NHK-Fintiv Despite Sotera(ish) Stipulation - IPWatchdog.com","headline":"Patent Filings Roundup: New Litigation-Funded Campaign; PTAB Denies Under NHK-Fintiv Despite Sotera(ish) Stipulation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOekpuR1JsRXdUN1c4SkhyN0Q4S3NIYXRVa0pLd1JWNnBqRnVhRkxpajh1SDlsMmZPRVJFWjhCWFVXcFlVc2t2SGN5ejJ0VXpOV2E0VnloRFJMd1JnWWU0ZFcxVVJKRDFRWjRnVHpoQkl0Mm1aenVnWE0wR3hackFkTFVFcEdReS03VFZzLVR2WnI0X2lWbldWMVgyU0JmMkNKM0ZHYmZZYmNWR2lZSW9NVEViUVBrZzVLa2YwRzMyWmdhVEdxZXYzTFBzYXdiZ0Y3LVBURUhQbFRHdFpv?oc=5","date":"2021-07-09","type":"patent","source":"IPWatchdog.com","summary":"Patent Filings Roundup: Second Mystery Entity Challenges $2.2 Billion VLSI/Fortress Patents; IP Edge Files Almost 50 New Complaints; NPE K.Mizra Targets ISPs - IPWatchdog.com","headline":"Patent Filings Roundup: Second Mystery Entity Challenges $2.2 Billion VLSI/Fortress Patents; IP Edge Files Almost 50 New","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":6},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}